<DOC>
	<DOCNO>NCT00074477</DOCNO>
	<brief_summary>The purpose study determine efficacy ( well drug work ) , safety , side effect paliperidone palmitate injection compare placebo treatment symptom schizophrenia adult . The placebo use study nutritional substance know 20 % Intralipid emulsion give patient require intravenous feeding .</brief_summary>
	<brief_title>Safety Efficacy Anti-Psychotic Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone palmitate aqueous suspension release paliperidone gradually period 1 month development provide sustain stable level paliperidone . This randomized ( patient assign different treatment group base solely chance ) , double-blind ( neither patient physician know placebo drug give dose ) , placebo-controlled , multicenter study patient schizophrenia . The study consist screen period ( maximum 5 day , include 3-day washout psychotropic medication antidepressant , applicable ) ; 7-day , open-label , oral run-in period ; 64-day double-blind treatment period . The total duration study approximately 11 week . Efficacy evaluate study use Positive Negative Symptom Scale Schizophrenia ( PANSS ) Clinical Global Impression - Severity ( CGI-S ) scale . Safety evaluate monitoring adverse event change clinical laboratory result , include prolactin level ; physical examination result ; tardive dyskinesia rat use Abnormal Involuntary Movement Scale ( AIMS ) , akathisia rat accord Barnes Akathisia Rating Scale ( BARS ) , extrapyramidal symptom evaluate use Simpson-Angus Rating Scale ( SAS ) ; electrocardiogram ( ECG ) ; vital sign measurement ; concomitant therapy . ER OROS paliperidone ( 6 12 mg ) IR paliperidone ( 2 4 mg ) oral dosage administer daily 7 day ( Day -7 -1 ) , follow i.m . injection paliperidone palmitate ( either 50 mg eq . 100 mg eq . ) , placebo Days 1 , 8 , 36 study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients diagnose schizophrenia least 1 year screen meet PANSS score criterion must agree hospitalization minimum 14 day body mass index ( BMI ) &lt; 35.0 kilogram ( kg ) /meter ( ) 2 . Patients involuntarily commit inpatient DSMIV Axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 3 month screen ( nicotine , caffeine dependence , history recreational use marijuana exclusionary ) decrease &gt; /=25 % PANSS score screen predose previous lack response 2 adequate trial antipsychotic treatment significant risk suicidal , homicidal , violent ideation behavior severe gastrointestinal narrowing ( pathologic iatrogenic ) current presence significant unstable medication condition treatment protocol disallow therapy clinically significant result screen laboratory ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>R092670</keyword>
	<keyword>antipsychotic</keyword>
</DOC>